Pharmacogenetics
Pharmacogenetics is the study of inherited genetic differences in drug metabolic pathways which can affect individual responses towords the drugs, both in their terms of therapeutic effect as well as adverse effects. In oncology, pharmacogenetics historically is the study of germ line mutations (e.g., single-nucleotide polymorphisms affecting genes coding for liver enzymes responsible for drug deposition and pharmacokinetics), whereas pharmacogenomics refers to somatic mutations in tumoral DNA leading to alteration in drug response.
- a. Translational Pharmacogenomics b. Cancer Pharmacogenomics c. Pharmacogenitics & Individualized therapy
Related Conference of Pharmacogenetics
June 18-19, 2026
16th International Conference on Human Genetics and Genetic Diseases
Singapore City, Singapore
June 18-19, 2026
19th International Conference on Genomics & Pharmacogenomics
Singapore City, Singapore
September 24-25, 2026
19th World Congress on Advances in Stem Cell Research and Regenerative Medicine
Paris, France
Pharmacogenetics Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- 3D Bioprinting, Organ Fabrication & Bioartificial Tissues - Stem Cell 2026 (Netherlands)
- Advanced Gene Therapeutics - Cell Signaling 2026 (France)
- Aging Biology, Longevity Science & Cellular Rejuvenation - Stem Cell 2026 (Netherlands)
- Animal Genetics - Genome 2026 (Singapore)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Bioengineering Therapeutics - Cell Signaling 2026 (France)
- Bioinformatics and Computational Biology - Genome 2026 (Singapore)
- Bioinformatics, AI Models & Predictive Regeneration - Stem Cell 2026 (Netherlands)
- Biomarkers and Microarrays - Genome 2026 (Singapore)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Genomics - Genome 2026 (Singapore)
- Cancer Stem Cells & Targeted Therapeutics - Stem Cell 2026 (Netherlands)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiac, Vascular & Musculoskeletal Regeneration - Stem Cell 2026 (Netherlands)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Cell Biology - Cell Signaling 2026 (France)
- Cell Culture and Bioprocessing - Cell Signaling 2026 (France)
- Cell Cycle/Proliferation - Cell Signaling 2026 (France)
- Cell Death and Viability - Cell Signaling 2026 (France)
- Cell Science and Stem Cell Research - Cell Signaling 2026 (France)
- Cellular Signaling - Cell Signaling 2026 (France)
- Cellular Therapies - Cell Signaling 2026 (France)
- Clinical genomics - Genome 2026 (Singapore)
- Clinical Translation of Stem Cell Therapies - Stem Cell 2026 (Netherlands)
- Clinical Trials and Research in Stem Cell in Cancer Therapy - Cell Signaling 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Commercialization, Biobanking & Industry Innovations - Stem Cell 2026 (Netherlands)
- Comparative Genomics - Genome 2026 (Singapore)
- Epidermis Stem Cell & Cancer Epidemiology - Cell Signaling 2026 (France)
- Epigenomics and Epigenetics - Genome 2026 (Singapore)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Ethical, Regulatory & Quality Control Frameworks - Stem Cell 2026 (Netherlands)
- Exosomes, Extracellular Vesicles & Cell-Free Therapeutics - Stem Cell 2026 (Netherlands)
- Functional Genomics - Genome 2026 (Singapore)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Gene Editing and Genetic Engineering - Genome 2026 (Singapore)
- Gene Editing, CRISPR Therapies & Regenerative Genomics - Stem Cell 2026 (Netherlands)
- Genetic Disorder - Genome 2026 (Singapore)
- Genomic Instability - Genome 2026 (Singapore)
- Genomic Medicine - Genome 2026 (Singapore)
- Human Gene Therapy - Cell Signaling 2026 (France)
- Immunotherapy - Cell Signaling 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Microbial Genomics - Genome 2026 (Singapore)
- Molecular Epigenetics - Cell Signaling 2026 (France)
- Nano-Therapy - Cell Signaling 2026 (France)
- Nanotechnology in Stem Cell - Cell Signaling 2026 (France)
- Next generation sequencing - Genome 2026 (Singapore)
- Nutrigenomics - Genome 2026 (Singapore)
- Personalized and Regenerative Medicine - Genome 2026 (Singapore)
- Pharmacogenomics - Genome 2026 (Singapore)
- Plant Genomics and Molecular Pharming - Genome 2026 (Singapore)
- Regeneration in Neurodegenerative & Spinal Cord Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Approaches in Diabetes & Metabolic Disorders - Stem Cell 2026 (Netherlands)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Immunology & Immune Modulation - Stem Cell 2026 (Netherlands)
- Regenerative Medicine - Cell Signaling 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Regulatory and Ethical Issues of Therapies. - Cell Signaling 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cell Engineering & Cellular Reprogramming - Stem Cell 2026 (Netherlands)
- Stem Cell in Drug Development - Cell Signaling 2026 (France)
- Stem Cell Therapies - Cell Signaling 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)
- Structural Genomics - Genome 2026 (Singapore)
- Tissue Engineering, Biomaterials & Smart Scaffolds - Stem Cell 2026 (Netherlands)
- Trends in Genomics and Pharmacogenomics - Genome 2026 (Singapore)